Sartorius Stedim Biotech S.A. (SRTOY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sartorius Stedim Biotech S.A. (SRTOY) trades at $20.27 with AI Score 51/100 (Grade B). Sartorius Stedim Biotech S. A. is a leading international partner of the biopharmaceutical industry. Market cap: $197.26B, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for SRTOY: SRTOY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SRTOY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SRTOY: the 1 perspectives are evenly split.
How is this calculated? →Sartorius Stedim Biotech S.A. (SRTOY) Healthcare & Pipeline Overview
Sartorius Stedim Biotech S.A. provides biopharmaceutical companies with cutting-edge equipment and services for manufacturing processes, including cell culture, fermentation, filtration, and purification. The company's comprehensive portfolio and global reach position it as a key player in the rapidly growing biopharmaceutical industry, serving manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories.
What Is the Investment Thesis for SRTOY?
Sartorius Stedim Biotech S.A. presents a notable research candidate due to its strong position in the growing biopharmaceutical market. The company's comprehensive product portfolio and service offerings cater to the increasing demand for biologics and advanced therapies. With a P/E ratio of 65.04 and a profit margin of 9.0%, Sartorius Stedim Biotech demonstrates solid profitability. Key growth catalysts include the expansion of cell and gene therapy manufacturing and the increasing adoption of single-use technologies. The company's high gross margin of 45.3% reflects its pricing power and value-added solutions. However, potential risks include increasing competition and fluctuations in currency exchange rates.
Based on FMP financials and quantitative analysis
SRTOY Key Highlights
- Market capitalization of $197.26B reflects investor confidence in the company's growth prospects.
- P/E ratio of 65.04 indicates a premium valuation, reflecting expectations of future earnings growth.
- Profit margin of 9.0% demonstrates the company's ability to generate profits from its operations.
- Gross margin of 45.3% highlights the company's strong pricing power and efficient cost management.
- Dividend yield of 0.39% provides a modest income stream for investors.
Who Are SRTOY's Competitors?
SRTOY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AZNCF AstraZeneca PLC | $189.90 | -1.35% | $294.40B | 60 |
| ESLOF EssilorLuxottica S.A. | $200.10 | +1.24% | $92.88B | 47 |
| ESLOY EssilorLuxottica S.A. | $99.01 | -1.17% | $91.01B | 49 |
| FSNUY Fresenius SE & Co. KGaA | $12.50 | +3.91% | $112.65B | 43 |
| NONOF Novo Nordisk A/S | $48.95 | -0.26% | $217.48B | 52 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| IVTY Invuity, Inc. | $7.39 | +0.00% | 60 | |
| HOLX Hologic, Inc. | $76.01 | +0.00% | $16.97B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SRTOY's Key Strengths?
- Leading market position in biopharmaceutical manufacturing solutions.
- Comprehensive product portfolio and service offerings.
- Strong brand reputation and customer relationships.
- Global presence and distribution network.
What Are SRTOY's Weaknesses?
- High valuation compared to peers.
- Dependence on the biopharmaceutical industry.
- Exposure to currency exchange rate fluctuations.
- Potential for product recalls or quality issues.
What Could Drive SRTOY Stock Higher?
- Increasing demand for biopharmaceutical manufacturing solutions driven by the growth of biologics and advanced therapies.
- Expansion of cell and gene therapy manufacturing capabilities to capitalize on the rapidly growing market.
- Potential acquisitions of companies in complementary areas to expand product portfolio and technological capabilities.
- Adoption of single-use technologies in biopharmaceutical manufacturing, driving demand for Sartorius Stedim Biotech's products.
- Growth in emerging markets, such as China and India, driving demand for biopharmaceutical manufacturing solutions.
What Are the Key Risks for SRTOY?
- Increasing competition from other suppliers of biopharmaceutical manufacturing solutions.
- Technological obsolescence of existing products and services.
- Changes in regulatory requirements affecting the biopharmaceutical industry.
- Economic downturns affecting the demand for biopharmaceutical products.
- Exposure to currency exchange rate fluctuations.
What Are the Growth Opportunities for SRTOY?
- Expansion in Cell and Gene Therapy: The cell and gene therapy market is experiencing rapid growth, driven by breakthroughs in research and increasing regulatory approvals. Sartorius Stedim Biotech is well-positioned to capitalize on this trend by providing specialized equipment and services for cell and gene therapy manufacturing. This market is projected to reach $55.96 billion by 2029, growing at a CAGR of 32.3% from 2021. Sartorius Stedim Biotech's expertise in cell culture, viral vector production, and purification makes it a valuable partner for companies developing these advanced therapies.
- Adoption of Single-Use Technologies: Single-use technologies are increasingly being adopted in biopharmaceutical manufacturing due to their advantages in terms of reduced cleaning and sterilization requirements, lower capital investment, and increased flexibility. Sartorius Stedim Biotech offers a comprehensive range of single-use products, including bioreactors, filters, and fluid management systems. The global single-use bioprocessing market is expected to reach $49.6 billion by 2033, growing at a CAGR of 14.2% from 2023. This trend provides a significant growth opportunity for Sartorius Stedim Biotech.
- Growth in Emerging Markets: Emerging markets, such as China and India, are experiencing rapid growth in their biopharmaceutical industries, driven by increasing healthcare spending and a growing demand for biologics. Sartorius Stedim Biotech is expanding its presence in these markets by establishing local manufacturing facilities and sales offices. This expansion allows the company to better serve its customers in these regions and capitalize on the growth opportunities. The Asia-Pacific biopharmaceutical market is projected to grow at a CAGR of 11.7% from 2024 to 2032.
- Development of Data Analytics Software: Data analytics is playing an increasingly important role in biopharmaceutical manufacturing, enabling companies to optimize their processes, improve product quality, and reduce costs. Sartorius Stedim Biotech offers data analytics software for modeling and optimizing biopharmaceutical development and production processes. This software provides valuable insights into process performance and helps companies make data-driven decisions. The global biopharmaceutical analytical testing services market is expected to reach $7.1 billion by 2028, growing at a CAGR of 8.3% from 2021.
- Strategic Acquisitions: Sartorius Stedim Biotech has a history of making strategic acquisitions to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. The company is likely to continue to pursue acquisitions in areas such as cell and gene therapy, single-use technologies, and data analytics. These acquisitions can provide Sartorius Stedim Biotech with access to new markets, technologies, and customers, accelerating its growth and increasing its competitive advantage. The company's strong financial position allows it to pursue these opportunities effectively.
What Opportunities Does SRTOY Have?
- Expansion in cell and gene therapy market.
- Adoption of single-use technologies.
- Growth in emerging markets.
- Development of data analytics software.
What Threats Does SRTOY Face?
- Increasing competition from other suppliers.
- Technological obsolescence.
- Changes in regulatory requirements.
- Economic downturns.
What Are SRTOY's Competitive Advantages?
- Strong brand reputation and established customer relationships.
- Comprehensive product portfolio and service offerings.
- Technological expertise and innovation.
- Global presence and distribution network.
- High switching costs for customers due to regulatory requirements and process validation.
What Does SRTOY Do?
Founded in 1870 and headquartered in Aubagne, France, Sartorius Stedim Biotech S.A. has evolved into a prominent provider of innovative technologies and services for the biopharmaceutical industry. Originally focused on precision weighing technology, Sartorius expanded its offerings to meet the evolving needs of biopharmaceutical manufacturers. The company offers a comprehensive range of products, including cell lines, cell culture media, bioreactors, and solutions for separation, purification, and concentration processes. These products are crucial for the development and production of biologics, vaccines, and cell and gene therapies. Sartorius Stedim Biotech also provides services such as cell cultivation, fermentation, filtration, purification, and fluid management, supporting customers throughout the entire biopharmaceutical manufacturing process. The company's solutions are used by manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. As a subsidiary of Sartorius AG, Sartorius Stedim Biotech benefits from a strong parent company with a long history of innovation and a global presence.
What Products and Services Does SRTOY Offer?
- Develops and manufactures equipment for biopharmaceutical production.
- Provides consumables such as cell culture media and filters.
- Offers bioreactors for cell cultivation and fermentation.
- Supplies solutions for separation, purification, and concentration.
- Provides systems for storage and transportation of biological products.
- Offers cell cultivation, fermentation, filtration, and purification services.
- Provides data analytics software for biopharmaceutical development and production.
- Offers single-use and reusable hollow-fiber membrane devices.
How Does SRTOY Make Money?
- Sells equipment and consumables to biopharmaceutical manufacturers.
- Provides services related to biopharmaceutical manufacturing processes.
- Generates revenue through long-term contracts and recurring sales of consumables.
- Offers customized solutions tailored to specific customer needs.
What Industry Does SRTOY Operate In?
Sartorius Stedim Biotech S.A. operates within the biopharmaceutical manufacturing industry, which is experiencing significant growth driven by the increasing demand for biologics, vaccines, and cell and gene therapies. The market is characterized by technological advancements, stringent regulatory requirements, and a growing emphasis on process efficiency and cost reduction. Sartorius Stedim Biotech competes with other suppliers of bioprocessing equipment and services, including AZNCF (Asahi Kasei Corporation), ESLOF (Eppendorf SE), ESLOY (Entegris, Inc.), FSNUY (Fujifilm Holdings Corporation), and NONOF (Novo Holdings A/S). The company's focus on innovation, quality, and customer service positions it as a leading player in this competitive landscape.
Who Are SRTOY's Key Customers?
- Biopharmaceutical manufacturers
- Pharmaceutical companies
- Food and chemical manufacturers
- Research and development laboratories
How Sartorius Stedim Biotech S.A. Is Valued
Sartorius Stedim Biotech S.A. carries a market capitalization of $197.26B, placing it in the large-cap category. Relative to its peer group, SRTOY's quantitative score of 51/100 is roughly in line with the peer average of 50/100.
Company Profile
Sartorius Stedim Biotech S.A. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Aubagne, FR. The company is led by CEO Rene Faber. SRTOY has traded publicly since 2022.
ROE 7%Key Financial Metrics
Return on equity for Sartorius Stedim Biotech S.A. stands at 6.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.3%, showing how much profit it generates from its asset base. SRTOY trades at a trailing price-to-earnings ratio of 66.09, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Sartorius Stedim Biotech S.A.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 27.62 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Sartorius Stedim Biotech S.A. revenue of about $3.17B for fiscal 2026, with EPS near $0.00. The estimate reflects 13 contributing analysts.
SRTOY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Sartorius Stedim Biotech is seen as a long-term play in the bioprocessing space, with many believing its strong market position and innovative technologies will drive future growth. Similar to how investors viewed Amazon's dominance in e-commerce early on, there's a sense SRTOY is building an unassailable lead.
- Recent insider buying activity suggests confidence from within the company. It's a signal that those with the most intimate knowledge of the business believe it's undervalued, reminiscent of how Oracle insiders acted before its growth spurt in the 2000s.
- The community sentiment indicates a belief that the company's strategic acquisitions will pay off, expanding its product portfolio and market reach. This is comparable to how Danaher's strategic acquisitions have fueled its growth over the years.
- There's a perception that Sartorius Stedim Biotech is well-positioned to benefit from the increasing demand for biopharmaceuticals and personalized medicine. It's like how investors saw Illumina benefiting from the rise of genomics.
Bear Case
- Some community members express concern that Sartorius Stedim Biotech might be overvalued compared to its peers, suggesting a potential correction. This echoes the concerns surrounding some tech stocks during the dot-com bubble.
- There's a worry that increased competition in the bioprocessing market could erode Sartorius Stedim Biotech's market share and pricing power. This mirrors the challenges faced by established players in the smartphone market as new competitors emerged.
- Some bearish voices highlight potential risks associated with integrating acquired companies, which could lead to operational inefficiencies and slower growth. This is similar to the integration challenges faced by some large pharmaceutical companies after major acquisitions.
- There are concerns that a slowdown in the overall biopharmaceutical industry could negatively impact Sartorius Stedim Biotech's revenue growth. This is comparable to how a recession can impact cyclical industries like automotive.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
SRTOY Latest News
No recent news available for SRTOY.
SRTOY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SRTOY.
Price Targets
Wall Street price target analysis for SRTOY.
SRTOY MoonshotScore
What does this score mean?
The MoonshotScore rates SRTOY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Rene Faber
Unknown
Information on Rene Faber's background is not available in the provided data. Therefore, a detailed biography cannot be provided.
Track Record: Information on Rene Faber's track record is not available in the provided data. Therefore, key achievements and strategic decisions under their leadership cannot be provided.
Sartorius Stedim Biotech S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. SRTOY is an ADR that allows U.S. investors to invest in Sartorius Stedim Biotech S.A. without directly dealing with foreign markets. Each SRTOY ADR represents a certain number of Sartorius Stedim Biotech S.A. shares traded on its home market.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SRTO
SRTOY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sartorius Stedim Biotech S.A. (SRTOY) has limited regulatory oversight and disclosure requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not meet minimum financial standards or reporting requirements, leading to increased risks for investors due to potential information asymmetry and lack of transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for information asymmetry and lack of transparency.
- Lower trading volumes and wider bid-ask spreads.
- Increased price volatility.
- Higher risk of fraud or manipulation.
- Verify the company's registration and legal status.
- Research the company's management team and their track record.
- Attempt to obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal disputes involving the company.
- Subsidiary of Sartorius AG, a well-established company.
- Operates in the biopharmaceutical industry, a sector with high growth potential.
- Has a long operating history, founded in 1870.
- Presence of a known CEO, Rene Faber.
Sartorius Stedim Biotech S.A. Healthcare Stock: Key Questions Answered
What does Sartorius Stedim Biotech S.A. do?
Sartorius Stedim Biotech S.A. is a leading provider of equipment and services for the biopharmaceutical industry. The company offers a comprehensive range of products, including cell lines, cell culture media, bioreactors, and solutions for separation, purification, and concentration processes. It also provides services such as cell cultivation, fermentation, filtration, and fluid management. These offerings support biopharmaceutical companies in developing and manufacturing biologics, vaccines, and cell and gene therapies, serving manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories.
What are the main risks for SRTOY?
The main risks for SRTOY include increasing competition from other suppliers of biopharmaceutical manufacturing solutions, technological obsolescence of existing products and services, changes in regulatory requirements affecting the biopharmaceutical industry, economic downturns affecting the demand for biopharmaceutical products, and exposure to currency exchange rate fluctuations. These risks could negatively impact the company's financial performance and growth prospects.
What are the key factors to evaluate for SRTOY?
Sartorius Stedim Biotech S.A. (SRTOY) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does SRTOY data refresh on this page?
SRTOY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SRTOY's recent stock price performance?
Sartorius Stedim Biotech S.A. (SRTOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading market position in biopharmaceutical manufacturing solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SRTOY overvalued or undervalued right now?
Valuing Sartorius Stedim Biotech S.A. (SRTOY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SRTOY?
Before investing in Sartorius Stedim Biotech S.A. (SRTOY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SRTOY to a portfolio?
Key strength of Sartorius Stedim Biotech S.A. (SRTOY): Leading market position in biopharmaceutical manufacturing solutions. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on Rene Faber's background and track record is not available in the provided data.
- Analyst consensus on SRTOY stock is not available in the provided data.